Recall of new lots of Losartan due to cancer risk

by



[ad_1]

Teva Pharmaceuticals USA, Inc. has issued a voluntary recall to the United States of 35 lots of loose Losartan Potassium USP tablets.

This recall is due to the detection of a carcinogenic impurity – N-nitroso-N-methyl-4-aminobutyric acid (NMBA).

The lots were sold exclusively to Golden State Medical Supply of Camarillo, California. Golden State Medical Supply packages this product in bulk under its own label and distributes it in bottles of 30, 90 and 1000 tablets.

To date, no adverse events related to the recalled batches have been reported to Teva.

The affected Losartan potassium tablets recalled are described as follows:

  • Losartan Potassium Tablets, USP 25 mg, are pale green teardrop-shaped, film-coated, biconvex tablets, with "LK 25" on one side and ">" on the other
  • Losartan potassium tablets, USP 100 mg, are oval-shaped, film-coated, dark green, biconvex tablets with "LK100" on one side and ">" on the other

    • More details on the reminder here.

    [ad_2]

    Source link